ArticleBiophysical journal2008
Effect of fengycin, a lipopeptide produced by Bacillus subtilis, on model biomembranes.
Article in Biophysical journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 248 citations in OpenAlex.
- Review
- Role of C17 fengycin B fromApplied and environmental microbiology · 2026Article
- Bacillaceae in Probiotics and Postbiotics: Applications, Functional Traits, Mechanisms and Outlook.Probiotics and antimicrobial proteins · 2026Review
- Differential Impact of Ergosterol on Yeast Membranes Exposed to Membrane-Targeting Antimicrobial Compounds.Chembiochem : a European journal of chemical biology · 2026Article
- Bacillus velezensis EU07 suppresses Fusarium graminearum via transcriptomic reprogramming.Applied microbiology and biotechnology · 2026Article
- Fengycin deficiency in Bacillus subtilis Pfen-1 increases antagonism and reveals a non-functional role against Sclerotinia sclerotiorum.Scientific reports · 2026Article
- Comprehensive characterization and genome-resolved insights into the probiotic potential of Bacillus sp. KNSH39 isolated from Litopenaeus vannamei intestine.World journal of microbiology & biotechnology · 2026Article
- Broad-Spectrum Antibacterial Action of Lipopeptides Derived from Bacillus smithii by Targeting Quorum Sensing.Probiotics and antimicrobial proteins · 2026Article
- Purification and Identification of Antimicrobial Peptides Produced by Thermophilic Bacteria Isolated from Hot Springs.Probiotics and antimicrobial proteins · 2026Article
- Mechanistic Insights for Microbiome Application in Plant Disease Resistance.Molecular plant pathology · 2026Review
- Kinetic modeling of multiple-strain artificial consortium to improve fengycin production of Bacillus subtilis.Biotechnology for biofuels and bioproducts · 2026Article
- Surfactin-Bacillaene Copathway Engineering Strategy Boosts Fengycin Production and Antifungal Activity inMicroorganisms · 2026Article
- Genomic and microecological insights into the biocontrol mechanisms ofFrontiers in microbiology · 2026Article
- Cyclic lipopeptides fromFrontiers in microbiology · 2026Article
- Antifungal Biocontrol in Sustainable Crop Protection: Microbial Lipopeptides, Polyketides, and Plant-Derived Agents.Journal of fungi (Basel, Switzerland) · 2025Review
- Comparative genomics analysis of Bacillus altitudinis G03 provides insights into its biocontrol and probiotic traits.BMC genomics · 2025Article
- Antimicrobial Potential of Marine Sponge-Associated Bacillus velezensis and Stutzerimonas stutzeri from the Indian Coast: A Genome Mining and Metabolite Profiling Approach.Current microbiology · 2025Article
- Bioinformatic strategies in metagenomics of chronic prostatitis.World journal of urology · 2025Article
- Cytotoxicity and Genome Characteristics of an Emetic Toxin-ProducingFoods (Basel, Switzerland) · 2025Article
- Genome mining of Bacillus thuringiensis strain SY49.1 reveals novel candidate pesticidal and bioactive compounds.Pest management science · 2025Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fengycin is a biologically active lipopeptide produced by several Bacillus subtilis strains. The lipopeptide is known to develop antifungal activity against filamentous fungi and to have hemolytic activity 40-fold lower than that of surfactin, another lipopeptide produced by B. subtilis. The aim of this work is to use complementary biophysical techniques to reveal the mechanism of membrane perturbation by fengycin. These include: 1), the Langmuir trough technique in combination with Brewster angle microscopy to study the lipopeptide penetration into monolayers; 2), ellipsometry to investigate the adsorption of fengycin onto supported lipid bilayers; 3), differential scanning calorimetry to determine the thermotropic properties of lipid bilayers in the presence of fengycin; and 4), cryogenic transmission electron microscopy, which provides information on the structural organization of the lipid/lipopeptide system. From these experiments, the mechanism of fengycin action appears to be based on a two-state transition controlled by the lipopeptide concentration. One state is the monomeric, not deeply anchored and nonperturbing lipopeptide, and the other state is a buried, aggregated form, which is responsible for membrane leakage and bioactivity. The mechanism, thus, appears to be driven mainly by the physicochemical properties of the lipopeptide, i.e., its amphiphilic character and affinity for lipid bilayers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.